tiprankstipranks
Blurbs

Analysts Conflicted on These Healthcare Names: Axsome Therapeutics (AXSM) and Checkmate Pharmaceuticals (CMPI)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Axsome Therapeutics (AXSMResearch Report) and Checkmate Pharmaceuticals (CMPIResearch Report).

Axsome Therapeutics (AXSM)

In a report released yesterday, Robert Hazlett from BTIG maintained a Buy rating on Axsome Therapeutics, with a price target of $62.00. The company’s shares closed last Tuesday at $40.92.

According to TipRanks.com, Hazlett is a 2-star analyst with an average return of 0.7% and a 33.5% success rate. Hazlett covers the Healthcare sector, focusing on stocks such as Intra-Cellular Therapies, Eiger Biopharmaceuticals, and Paratek Pharmaceuticals.

Axsome Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $96.50, a 139.7% upside from current levels. In a report released yesterday, Guggenheim also maintained a Buy rating on the stock.

See today’s best-performing stocks on TipRanks >>

Checkmate Pharmaceuticals (CMPI)

BTIG analyst Kaveri Pohlman maintained a Hold rating on Checkmate Pharmaceuticals yesterday. The company’s shares closed last Tuesday at $10.35.

According to TipRanks.com, Pohlman ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -35.3% and a 14.0% success rate. Pohlman covers the Healthcare sector, focusing on stocks such as Sonnet BioTherapeutics Holdings, Oncternal Therapeutics, and Mersana Therapeutics.

Currently, the analyst consensus on Checkmate Pharmaceuticals is a Moderate Buy with an average price target of $6.00.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on AXSM:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed